Related Experiment Video
Updated: Apr 4, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of
Juan F Rodriguez-Riascos1, Dravid Navale1, Aakash Somappa1
1Department of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ (J.F.R.-R., D.N., A.S., L.R.S., W.-K.S., K.S.).
Insights
Discontinuing oral anticoagulation after atrial fibrillation catheter ablation is safe, with a low incidence of stroke. Larger studies are needed to confirm net clinical benefit, especially in high-risk patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Electrophysiology
Background:
- Catheter ablation is a common treatment for atrial fibrillation.
- The impact of ablation on thromboembolic risk and oral anticoagulation (OAC) needs further clarification.
- Evidence on long-term antithrombotic strategies post-ablation is limited.
Purpose of the Study:
- To evaluate randomized controlled trial evidence on antithrombotic strategies after atrial fibrillation catheter ablation.
- To synthesize data on thromboembolic risk and OAC discontinuation post-ablation.
- To assess the role of catheter ablation in managing antithrombotic therapy.
Main Methods:
- Systematic literature search of major databases (MEDLINE/PubMed, Embase, Cochrane).
- Inclusion of randomized controlled trials comparing antithrombotic strategies post-ablation.
- Frequentist network meta-analysis and pooled incidence meta-analysis.
Main Results:
- Four trials with 3924 patients were analyzed.
- No significant difference in stroke incidence between OAC, left atrial appendage occlusion, and no antithrombotic therapy.
- Pooled stroke incidence was 0.23 per 100 person-years in patients discontinuing OAC post-ablation.
Conclusions:
- Thromboembolic event incidence is low in patients discontinuing OAC after successful ablation.
- Limited events restrict evaluation of net clinical benefit.
- Larger studies with longer follow-up are required to validate safety, especially in high-risk populations.
Background:
Catheter ablation for atrial fibrillation is a widely used rhythm-control strategy, yet its role in reducing thromboembolic risk and enabling oral anticoagulation (OAC) discontinuation remains uncertain. This meta-analysis aims to comprehensively synthesize and evaluate randomized controlled trial evidence supporting long-term antithrombotic strategies in patients with atrial fibrillation undergoing catheter ablation.
Methods:
A systematic literature search was performed in MEDLINE/PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials evaluating antithrombotic strategies after catheter ablation for atrial fibrillation. The primary outcome was ischemic stroke. A frequentist network meta-analysis comparing reported treatment arms, along with a pooled incidence meta-analysis for outcomes of interest, was conducted.
Results:
Four randomized controlled trials, including 3924 patients, met the inclusion criteria. Three trials compared long-term OAC continuation versus OAC discontinuation, and 1 compared OAC continuation with left atrial appendage occlusion after catheter ablation. No significant differences in stroke incidence were observed when comparing OAC or left atrial appendage occlusion with no antithrombotic therapy (incidence rate ratio, 0.90 [95% CI, 0.02-33.85]; P=0.95; incidence rate ratio, 0.79 [95% CI, 0.00-241.01]; P=0.94, respectively). Among patients who discontinued antithrombotic therapy without undergoing left atrial appendage occlusion (n=1161), with 2864 cumulative person-years of follow-up, the pooled incidence of stroke was 0.23 events per 100 person-years (95% CI, 0.02-2.43; I2=0%).
Conclusions:
This analysis reinforces that, across randomized data, the incidence of thromboembolic events in patients who discontinued OAC after successful ablation remained low. However, the evaluation of net clinical benefit is limited by the low number of events across all treatment arms, underscoring the need for larger studies with prolonged follow-up to further validate the safety of this strategy, particularly in higher-risk populations.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Cardiac Catheterization IV: Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Atherosclerosis III: Management